Clinical Benefit Rate (CBR) is defined as the percentage of advanced cancer patients who achieve complete remission, partial remission, or at least six months of stable disease after treatment.

This article summarized the latest R&D progress of efalizumab, the Mechanism of Action for efalizumab, and the drug target R&D trends for efalizumab.

BridgeBio Pharma and National Resilience Inc., which focus on genetic diseases, cancer pharmaceuticals, and tech-driven biomanufacturing respectively, announced a partnership to develop and produce BBP-812 and BBP-631, gene therapies for Canavan disease and congenital adrenal hyperplasia.

Proteolysis Targeting Chimeras (PROTACs) technology is a new protein degradation strategy that has emerged in recent years.

Pathological Complete Response (pCR) is commonly used as a surrogate marker for breast cancer and is defined as the absence of residual invasive cancer in the resected breast tissue and evaluated regional lymph node.

This article summarized the latest R&D progress of dorzolamide hydrochloride, the Mechanism of Action for dorzolamide hydrochloride, and the drug target R&D trends for dorzolamide hydrochloride.

Disc Medicine has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.

This article summarized the latest R&D progress of dorzagliatin, the Mechanism of Action for dorzagliatin, and the drug target R&D trends for dorzagliatin.

Complete response (CR) is defined as the absence of detectable tumor in the patient's body. Radiology and histopathology are used to measure CR, serving as surrogate or primary endpoints depending on the specific disease or use scenario.

Kineta, Inc., a clinical-stage biotech firm specializing in unique cancer immunotherapies, has shared updates on their ongoing Phase 1/2 clinical trial of KVA12123 for advanced solid tumor patients.

Duration of Response (DoR) is defined as the time from randomization to disease progression or death for patients who achieve complete or partial alleviation.

Oncolytic virus (OVs) refers to a generic name for viruses that naturally exist or are genetically edited to selectively kill tumor cells.